Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat maintenance after HSCT in high-risk MDS or AML
NCT01451268Phase 2Unknown
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Jan 2011
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Universitätsklinikum Frankfurt. Status: unknown.
02
Drugs
panobinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01451268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01451268.